NCT00819221View on ClinicalTrials.gov

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

PHASE1TerminatedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

January 5, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

December 22, 2021

Conditions

Solid Tumors

Interventions

DRUG

AZD2281

capsules, oral, bd, 2 months

DRUG

liposomal doxorubicin

once every 4 weeks at 40mg/m2

Trial Locations (3)

20133

Research Site, Milan

CH-6500

Research Site, Bellinzona

CH-7000

Research Site, Chur

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY